Middle East War Rattles Global Markets as Oil Tops $100 and Dollar Surges 
Oil Prices Climb as Iran Reviews U.S. Peace Proposal Amid Middle East Tensions 
AWS Bahrain Region Disrupted by Drone Activity Amid Middle East Conflict 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026 
9 Tips for Avoiding Tax Season Cyber Scams 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Gold Prices Surge on U.S.-Iran Ceasefire Reports 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Gold Prices Climb as Middle East Ceasefire Talks Stir Market Optimism 
Explosion and Fire Erupt at Valero Oil Refinery in Port Arthur, Texas 
Japan Eyes Oil Futures Intervention to Stabilize Yen Amid Middle East Crisis 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
